BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript

Core Insights - BridgeBio celebrates its 10th anniversary this year, highlighting a decade of progress in the biotechnology sector focused on genetic diseases [2] - The company has developed a highly efficient R&D engine, with three approved products and the potential for three more in the next 12 months [3] - BridgeBio has generated nearly 20 Investigational New Drug (IND) applications and has positively impacted almost 10,000 patient lives, with expectations for many more in the future [3] Company Overview - The company has established itself as one of the most efficient R&D engines in the biotechnology industry, particularly for patients with genetic diseases [3] - BridgeBio has a strong pipeline, with three approved products and additional candidates expected to be submitted for approval soon [3] Industry Context - The biotechnology sector is increasingly focused on developing treatments for genetic diseases, with companies like BridgeBio leading the way in R&D efficiency and patient impact [3]